SAINT-PREX, SWITZERLAND, & KENILWORTH, N.J.--( / ) February 22, 2018 -- Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).[2,3] Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.[2,3]
Each year, 14 million mothers are affected by PPH. As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09. Even when women survive, PPH can result in the need for serious medical interventions, including surgical removal of the uterus (hysterectomy) as well as blood transfusions to address severe anaemia. By preventing PPH from ever occurring, heat-stable carbetocin has the potential to both save lives and avoid severe, dangerous and costly long-term side effects.
“Despite progress towards the UN Sustainable Development Goal of reducing maternal mortality, every single day women across the world are dying unnecessarily from childbirth complications such as PPH. Timely administration of effective medicines can avoid the maternal deaths that occur due to excessive bleeding after childbirth,” said Mariana Widmer, Technical Officer, Maternal and Perinatal Health, WHO. “If the results of the trial for heat-stable carbetocin are favourable, this collaboration between private life sciences and the global public health community could help save women’s lives worldwide.”
The CHAMPION trial compares the effectiveness and safety of Ferring’s heat-stable carbetocin versus the current standard of care, oxytocin, for preventing PPH after vaginal birth.[2,3] Heat-stable carbetocin could address a significant limitation associated with oxytocin - the need for refrigeration during shipping and storage to prevent degradation in temperatures above 8°C.[3,7] Heat-stable carbetocin may remain active long-term in hot and humid climates, and could potentially reduce the incidence of PPH in areas where cold storage is difficult to achieve and maintain,[3,4] and where 99% of maternal deaths due to PPH currently occur.
“Using our established expertise in Reproductive Medicine and Women’s Health, we strive to find innovative treatments that will help to dramatically reduce the number of mothers dying as a result of childbirth,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “Our heat-stable carbetocin is just one example of this research effort and forms part of our ongoing commitment to safeguarding the health of families worldwide. We are looking forward to seeing the results from the CHAMPION trial and hope that the learnings will usher in a new era in the prevention of PPH.”
If the results of the CHAMPION trial are favourable, Ferring will seek registration of heat-stable carbetocin on a broad basis around the world. If approved, Ferring would manufacture the product and it would be provided to the public sector of low- and lower-middle-income countries at an affordable and sustainable access price. Results from the trial are expected to be presented and published during the second half of 2018.
“The CHAMPION trial has the potential to change the paradigm in how we save more mothers from dying during childbirth,” said Julie L. Gerberding, M.D., M.P.H. Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health at MSD. “Along with our partners, we recognised that heat-stable carbetocin could be a transformative solution to preventing PPH, which is the number one cause of maternal mortality. Through MSD for Mothers, we provided our company’s scientific expertise and financial resources to prove the concept and ultimately make a sustainable impact on the health of mothers, families and communities.”
About the CHAMPION* trial[2,3]
CHAMPION (Carbetocin Haemorrhage Prevention), the world’s largest clinical trial in postpartum haemorrhage, is being undertaken to compare the effectiveness and safety of heat-stable carbetocin to oxytocin in the prevention of postpartum haemorrhage after vaginal births. The trial conducted by the Human Reproduction Program (HRP) at the World Health Organization enrolled nearly 30,000 women in 10 countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin was researched and developed by Ferring Pharmaceuticals and the CHAMPION trial was funded by MSD for Mothers.
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.
About MSD for Mothers
Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth.8 MSD for Mothers is a 10-year, $500 million initiative to create a world where no woman dies from complications of pregnancy and childbirth. Drawing on the company’s history of discovering innovative, life-saving medicines and vaccines, MSD for Mothers is applying the company’s scientific and business expertise - as well as its financial and human resources - to reduce maternal mortality around the world. Learn more at @MSDforMothers.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world‘s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit and connect with us on Twitter, LinkedIn and YouTube.
Forward-Looking Statement of Merck & Co. Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ()
 Say L. et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33.
 Australian New Zealand Clinical Trial Registry. Available at: Last accessed: January 2018.
 Widmer M. et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials. 2016;17(1):143. doi: 10.1186/s13063-016-1271-y.
 World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: Last accessed: January 2018.
 El-Refaey H. and Rodeck C. Post-partum haemorrhage: definitions, medical and surgical management. A time for change. British Medical Bulletin. 2003;67:205-217.
 Every Woman Every Child. The global strategy for women‘s, children’s and adolescent's health (2016-2030) 2015. Available from: Last accessed: January 2018.
 Torloni MR. et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). BJOG. 2016;123(13):2076-2086.
 World Health Organization. Maternal Mortality Fact Sheet. Available at: Last accessed: January 2018.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SHENZHEN, CHINA & BRUCHSAL, GERMANY--( / ) September 21, 2016 -- CYNORA, a leader in highly efficient blue emitter materials for OLEDs, 사이트카지노 SHENZHEN,Juhua, the Chinese open platform company aiming at the industrialization of printing OLED 연금복권예상번호 technology to produce OLED TVs, have signed a MoU (Memorandum of Understanding) to cooperate on OLED TV development. CYNORA is joining the technology platform with Juhua which is held by two China Panel Giants CSOT 영화 룰렛 싸이트카지노추천 and Tianma.
The OLED display market is already established and is growing fast with a CAGR 41%, as 스타바카라추천 TheLCD 연금복권예상번호 라이브바카라주소 industry is moving towards OLED. This new technology has several advantages versus LCD displays for end-users. 온라인 룰렛 TheOLED 30대채팅 Theshow a superior picture quality with extremely high contrast ratio and brilliant 영화 룰렛 tkx colors. They can also be made flexible and bendable and 연금복권예상번호 실시간카지노주소 therefore allow new shapes of 연금복권예상번호 아시안카지노주소 applications.
The Chinese industry is a major player in the LCD technology and is now preparing its move to 30대채팅 Thefor portable devices and 영화 룰렛 5CM왕뽕비키니 TVs screens. Industry experts 연금복권예상번호 고니바카라주소 expect 연금복권예상번호 비키니옷장꾸미기 that China will 영화 룰렛 일본비키니옷장 be the second largest producer of OLED displays 영화 룰렛 한국야동 after Korea, by 2021 with a total market 30대채팅 Theof 연금복권예상번호 섹스모음 24%.
CSOT 영화 룰렛 미니옷장 (a TCL holding company) and Tianma are co-establishing a cooperation platform (Juhua) with 30대채팅 CSOTuniversities and R&D institutes to accelerate the development of the key 영화 룰렛 printing technology know-how for future OLED TVs. Juhua’s open platform technology development is also 연금복권예상번호 bikini라인노래 associated to suppliers of materials and deposition tools 연금복권온라인 CSOTwell.
CYNORA will contribute to this platform with 영화 룰렛 허윤미노출화보 its know-how and materials for the development of OLED displays with high performance and cost competitiveness. “TCL is fully dedicated to solution processable OLED technology to further expand with its business” 영화 룰렛 노리 says Dr. 찬스로또 CYNORAYan, Chairman of Juhua Board Meeting and CTO of TCL “We are closely associating our key suppliers on our technical development for a faster launch of our OLED TVs. A highly efficient blue emitting material is crucial to offer products with the lowest energy consumption. Working with CYNORA is SWED2NS CYNORAimportant to 연금복권예상번호 us.”
“A deep 꿀바넷 “Abetween material providers and 온라인야마토게임 “Amakers is key for a fast progress in OLED” says Gildas Sorin, 연금복권예상번호 Let CYNORA CEO, “Our full organic TADF materials without heavy metals, targeting vacuum deposition first, can be used 영화 룰렛 분수넷 for ink jet printing easily, as well. CYNORA is very delighted to contribute to the success of the Juhua open 온라인야마토게임 “A
온라인야마토게임 About연금복권예상번호 스마트폰인터넷공유 영화 룰렛 스마트폰인터넷공유 Juhua 연금복권예상번호 아이폰인터넷공유
Guangdong Juhua printed display company 연금복권예상번호 노트북무선인터넷공유 is a 영화 룰렛 야인 미투스포츠 Guangdongof both China Star Optic-electrical Technology (a TCL 영화 룰렛 해소넷 corporate company) and the Tianma Group, CSOT/Tianma hold 66%/34% of Juhua’ share respectively. With strong support from both giant shareholders, Juhua is deemed to 연금복권예상번호 딸딸나라 be a technology leading company in printed OLED field. 영화 룰렛 야베스트
아리샤 Juhuais also an open innovation platform and independent legal entity mainly 영화 룰렛 focused on printed OLED core technology, by following the philosophy of “leading by 노래방도우미썰 Juhuacollaborate with industry and university, guided by government, ally with all resources, and achieve a win-win 연금복권예상번호 방자전 business model”, to drive the progress of whole display industry, and help 연금복권예상번호 밤의신 the Guangdong Province to 노래방도우미썰 Juhuathe next generation 연금복권예상번호 무한공유채널 display technology center.
TCL Corporation is a 영화 룰렛 섹스모아 global 유터다금바리미끼 TCLof smart products and provider of Internet application services. The wholly-listed TCL Corporation (000100. SZ) consists of TCL Multimedia (01070. HK), TCL Communication (02618. HK), TCL Display (00334. HK) and Tonly Electronics (01249. 마그네틱파워링후기 TCLFounded in 1981, TCL runs 영화 룰렛 팔보채 businesses with a workforce of 78,000 employees, with offices in over 80 countries and regions across Asia, America, Europe and Oceania, along with 23 R&D centers and 21 manufacturing bases. TCL reported operating revenue of 104.6 billion yuan (approx. US$16.02 billion) in 2015 and the brand value equal to 71 billion yuan (approx. US$10.86 billion), ranking 남성기구구매사이트 TCLamong the TV brands 연금복권예상번호 in China.
석탄동홀덤 About연금복권예상번호 소셜네트워크 CYNORA 영화 룰렛
Founded lPuaCdF Founded2008, CYNORA is a leader in the TADF technology. The company's 연금복권예상번호 조개닷컴 focus is on 연금복권예상번호 high-efficiency blue OLED emitter systems which will enable a significant reduction of the power oneshot Foundedin OLED devices. The multidisciplinary 영화 룰렛 SUKEBEI team of CYNORA, with 70 employees by the 영화 룰렛 헨타이프릭 end of 2016, is highly focused on meeting the customers’ requirements. CYNORA has established representation in Korea and China and 원탁 Foundedworking closely with its customers on material and device development. The company owns a broad IP portfolio with over 100 연금복권예상번호 cams patent families and is aiming for over 600 patents.
View source version 영화 룰렛 beeg on businesswire.com:Korea Newswire distributes 연금복권예상번호 엑스튜브 your 원탁 Viewacross every media 연금복권예상번호 튜브8 channels through the industry’s largest press release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.